Symptom profiles of treated and untreated cohorts
| Symptom group | Number of patients reporting symptom | |||
| HRA treated (26) | Untreated (23) | |||
| Initial assessment | Follow-up assessment | Initial assessment | Follow-up assessment | |
| Fatigue | 17/26 | 12/26 | 15/23 | 15/23 |
| Constitutional upset | 10/26 | 7/26 | 16/23 | 14/23 |
| Breathlessness | 6/26 | 5/26 | 9/23 | 8/23 |
| Post-exertional malaise | 12/26 | 11/26 | 16/23 | 14/23 |
| Chest pain | 13/26 | 6/26 | 6/23 | 5/23 |
| Neurologic | 13/26 | 4/26 | 17/23 | 14/23 |
| Neuropsychiatric | 7/26 | 4/26 | 11/23 | 9/23 |
| Dysautonomia | 4/26 | 4/26 | 6/23 | 4/23 |
| Gastrointestinal | 8/26 | 5/26 | 5/23 | 5/23 |
| Dermatological | 9/26 | 3/26 | 7/23 | 7/23 |
| ENT | 10/26 | 8/26 | 7/23 | 8/23 |
| Average symptom burden per patient±SD | 4.28±1.70 | 2.68±1.97 | 4.91±2.57 | 4.39±2.49 |
ENT, ear, nose and throat; HRA, histamine receptor antagonist.